About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) group arises from the merger of two VHIR groups, the Clinical Biochemistry group and the Drug Delivery and Targeting group, which they develop preclinical and clinical research in the diagnosis and therapy of different diseases.
With a direct link to the Clinical Biochemistry service of the Vall d'Hebron Hospital, our scope of action ranges from the analysis of massive data coming from the service, the development of diagnostic and prognostic biomarkers, evaluation of existing therapies and the development of new therapeutic strategies based on nanotechnology.
In terms of specific pathologies or indications, the group has an extensive track record in basic and applied research in cancer (new biomarkers, therapeutic targets and new treatments), metabolopathies (biomarkers and improvements in enzyme replacement therapy), kidney disease and liver disease.
IP: Concepció Jacobs Cachá Collaborators: - Funding agency: Fundació La Marató de TV3 Funding: 199966.31 Reference: 202017/10 Duration: 30/03/2021 - 31/12/2024
IP: Ibane Abasolo Olaortua Collaborators: Joaquin Seras Franzoso, Guillem Pintos Morell, Zamira Vanessa Diaz Riascos, Simon Schwartz Navarro, Julia German Cortes Funding agency: EUROPEAN COMMISSION Funding: 457250 Reference: MIMIC-KEY_H2020-FETPROACT-2020 Duration: 01/06/2021 - 31/05/2025
IP: Ibane Abasolo Olaortua Collaborators: - Funding agency: Agence Nationale de la Recherche Funding: 0.01 Reference: EVERETT_ANR-BIOPNSE2020 Duration: 01/11/2022 - 31/10/2025
IP: Melchor Carbonell Socias Collaborators: Julio Herrero García, Nerea Maiz Elizaran, Anna Suy Franch, Maria del Pilar Reimundo Diaz-Fierros Funding agency: Fundació La Marató de TV3 Funding: 49988.75 Reference: 202128-32 Duration: 20/10/2021 - 19/10/2024
PMID: 38139013 Journal: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES Year: 2023 Reference: Int J Mol Sci. 2023 Dec 6;24(24):17185. doi: 10.3390/ijms242417185. Impact factor: Publication type: Paper in international publication Authors: Adombi, Caroline Melanie; Buti, Maria; Campos, Carolina; Colomer-Castell, Sergi; Cortese, Maria Francesca; Esteban, Juan Ignacio; Garcia-Cehic, Damir; Gregori, Josep; Ibanez-Lligona, Marta; Quer, Josep et al. DOI: 10.3390/ijms242417185
PMID: 38188336 Journal: Frontiers in Medicine Year: 2023 Reference: Front Med (Lausanne). 2023 Dec 20;10:1301001. doi: 10.3389/fmed.2023.1301001. eCollection 2023. Impact factor: Publication type: Paper in international publication Authors: Bajana, Ivan; Camos, Silvia; Chiscano-Camon, Luis; Ferrer, Ricard; Ferrer-Costa, Roser; Martin, Laura; Martin-Rodriguez, Cristina; Palmada, Clara; Perez-Carrasco, Marcos; Plata-Menchaca, Erika P et al. DOI: 10.3389/fmed.2023.1301001
The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.
The European Rare Diseases Research Alliance (ERDERA) kicked off this September, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond.
Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.
